Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 98

1.

Recurrent Glioblastoma Treated with Recombinant Poliovirus.

Desjardins A, Gromeier M, Herndon JE 2nd, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD.

N Engl J Med. 2018 Jul 12;379(2):150-161. doi: 10.1056/NEJMoa1716435. Epub 2018 Jun 26.

2.

Heparan Sulfate Binding Coxsackievirus B3 Strain PD: A Novel Avirulent Oncolytic Agent Against Human Colorectal Carcinoma.

Hazini A, Pryshliak M, Brückner V, Klingel K, Sauter M, Pinkert S, Kurreck J, Fechner H.

Hum Gene Ther. 2018 Jun 20. doi: 10.1089/hum.2018.036. [Epub ahead of print]

PMID:
29739251
3.

Traveling treatment: medical tourism in the emerging era of potentially transmissible therapeutics.

Hreh M, Cohn CS, McKenna D, Gniadek TJ.

Transfusion. 2017 Oct;57(10):2549-2550. doi: 10.1111/trf.14276. No abstract available.

PMID:
28944545
4.

Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs.

Brown MC, Holl EK, Boczkowski D, Dobrikova E, Mosaheb M, Chandramohan V, Bigner DD, Gromeier M, Nair SK.

Sci Transl Med. 2017 Sep 20;9(408). pii: eaan4220. doi: 10.1126/scitranslmed.aan4220.

5.

Oncolytic coxsackievirus therapy as an immunostimulator.

Miyamoto S, Sagara M, Kohara H, Tani K.

Rinsho Ketsueki. 2017;58(8):977-982. doi: 10.11406/rinketsu.58.977. Review. Japanese.

PMID:
28883283
6.

Bioselection of coxsackievirus B6 strain variants with altered tropism to human cancer cell lines.

Svyatchenko VA, Ternovoy VA, Kiselev NN, Demina AV, Loktev VB, Netesov SV, Chumakov PM.

Arch Virol. 2017 Nov;162(11):3355-3362. doi: 10.1007/s00705-017-3492-0. Epub 2017 Aug 1.

PMID:
28766058
7.

Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus.

Miles LA, Burga LN, Gardner EE, Bostina M, Poirier JT, Rudin CM.

J Clin Invest. 2017 Aug 1;127(8):2957-2967. doi: 10.1172/JCI93472. Epub 2017 Jun 26.

8.

Seneca Valley Virus Suppresses Host Type I Interferon Production by Targeting Adaptor Proteins MAVS, TRIF, and TANK for Cleavage.

Qian S, Fan W, Liu T, Wu M, Zhang H, Cui X, Zhou Y, Hu J, Wei S, Chen H, Li X, Qian P.

J Virol. 2017 Jul 27;91(16). pii: e00823-17. doi: 10.1128/JVI.00823-17. Print 2017 Aug 15.

9.

MicroRNA-based Regulation of Picornavirus Tropism.

Ruiz AJ, Russell SJ.

J Vis Exp. 2017 Feb 6;(120). doi: 10.3791/55033.

PMID:
28287517
10.

Oncolytic Virotherapy for the Treatment of Malignant Glioma.

Foreman PM, Friedman GK, Cassady KA, Markert JM.

Neurotherapeutics. 2017 Apr;14(2):333-344. doi: 10.1007/s13311-017-0516-0. Review.

11.

Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models.

Holl EK, Brown MC, Boczkowski D, McNamara MA, George DJ, Bigner DD, Gromeier M, Nair SK.

Oncotarget. 2016 Nov 29;7(48):79828-79841. doi: 10.18632/oncotarget.12975.

12.

Sensitivity of C6 Glioma Cells Carrying the Human Poliovirus Receptor to Oncolytic Polioviruses.

Sosnovtseva AO, Lipatova AV, Grinenko NF, Baklaushev VP, Chumakov PM, Chekhonin VP.

Bull Exp Biol Med. 2016 Oct;161(6):821-825. Epub 2016 Oct 26.

PMID:
27783287
13.

Oncolytic Seneca Valley Virus: past perspectives and future directions.

Burke MJ.

Oncolytic Virother. 2016 Sep 6;5:81-9. doi: 10.2147/OV.S96915. eCollection 2016. Review.

14.

Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports.

Alberts P, Olmane E, Brokāne L, Krastiņa Z, Romanovska M, Kupčs K, Isajevs S, Proboka G, Erdmanis R, Nazarovs J, Venskus D.

APMIS. 2016 Oct;124(10):896-904. doi: 10.1111/apm.12576. Epub 2016 Jul 26.

PMID:
27457663
15.

Senecavirus A.

Segalés J, Barcellos D, Alfieri A, Burrough E, Marthaler D.

Vet Pathol. 2017 Jan;54(1):11-21. doi: 10.1177/0300985816653990. Epub 2016 Jul 11. Review.

PMID:
27371541
16.

The Role of Intralesional Therapies in Melanoma.

Agarwala SS.

Oncology (Williston Park). 2016 May;30(5):436-41. Review.

17.

Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies.

Uusi-Kerttula H, Davies J, Coughlan L, Hulin-Curtis S, Jones R, Hanna L, Chester JD, Parker AL.

Oncotarget. 2016 May 10;7(19):27926-37. doi: 10.18632/oncotarget.8545.

18.

Therapeutic Use of Native and Recombinant Enteroviruses.

Ylä-Pelto J, Tripathi L, Susi P.

Viruses. 2016 Feb 23;8(3):57. doi: 10.3390/v8030057. Review.

19.

MicroRNA-Detargeted Mengovirus for Oncolytic Virotherapy.

Ruiz AJ, Hadac EM, Nace RA, Russell SJ.

J Virol. 2016 Mar 28;90(8):4078-4092. doi: 10.1128/JVI.02810-15. Print 2016 Apr.

20.

Enhancing the Tumor Selectivity of a Picornavirus Virotherapy Promotes Tumor Regression and the Accumulation of Infiltrating CD8+ T Cells.

Bell MP, Pavelko KD.

Mol Cancer Ther. 2016 Mar;15(3):523-30. doi: 10.1158/1535-7163.MCT-15-0459. Epub 2016 Jan 28.

Supplemental Content

Loading ...
Support Center